New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio
Data demonstrating long-term comparable efficacy, safety and immunogenicity of BENEPALI® (etanercept) and FLIXABI® (infliximab) were presented by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen (NASDAQ: BIIB), at the Annual European Congress of Rheumatology (EULAR 2016), held 8–11 June in London, UK. Results showed that in patients who were switched from the reference product Enbreli to BENEPALI, there were no treatment-emergent safety or immunogenicity issues, and efficacy was sustained for up to two years.ii Comparable safety, immunogenicity and sustained efficacy were also demonstrated in patients who were switched from Remicadeiii to FLIXABI, compared with those who continued on Remicade.iv BENEPALI and FLIXABI were both approved by the European Commission (EC) earlier this year and are commercialized in Europe by Biogen.
Additional data presented at the congress include results from Phase I and Phase III studies of SB5, an adalimumab biosimilar candidate referencing Humira®.v Results showed sustained and comparable efficacy, and comparable safety and immunogenicity profiles over 52 weeks in patients who transitioned from Humira to SB5 at Week 24, compared with patients who continued to receive the reference productvi and those who continued on SB5.
“Biologics have benefitted a large number of patients, effectively revolutionizing the treatment of rheumatic diseases. Biosimilars can help more patients gain access and benefit from biologic therapies, while providing cost savings to healthcare systems and supporting future healthcare innovation,” said Alpna Seth, Ph.D., Senior Vice President and Global Head of the Biosimilars Business Unit at Biogen. “The data presented by our partners Samsung Bioepis at EULAR reinforce the comparable safety and efficacy of our anti-TNF biosimilars portfolio in patients living with chronic inflammatory conditions, including rheumatoid arthritis.”
“The integration of biosimilars in routine clinical practice is a crucial step to help patients’ access disease modifying biologic therapies they can significantly benefit from,” said Professor John Isaacs, Director of the Institute of Cellular Medicine at Newcastle University and consultant rheumatologist at the Freeman Hospital. “Patient safety is of the utmost importance, and we are beginning to see a solid bank of data that, together with real-world evidence, will further establish the role of biosimilars.”
The posters presented at the Annual European Congress of Rheumatology (EULAR 2016) by Samsung Bioepis include:
- Emery P, et al. Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients With Rheumatoid Arthritis: Comparison Between Continuing SB4 and Switching From Etanercept Reference Product to SB4 [THU0150] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- Smolen JS, et al. Comparable Safety and Immunogenicity and Sustained Efficacy After Transition to SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients With Rheumatoid Arthritis: Results of Phase III Transition Study [FRI0162] – Friday, June 10, 2016, 11.50am BST, Poster Area
- Choe J-Y, et al. Efficacy and Safety Analysis by Overall Anti-drug Antibody Results up to Week 30 in Patients with Rheumatoid Arthritis Treated with SB2 (an Infliximab Biosimilar) or Infliximab Reference Product in Phase III study [THU0140] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- Durez P, et al. The 54-week Results of Interferon-γ Release Assay in A Phase III Study Comparing SB2, An Infliximab Biosimilar, to Infliximab Reference Product in Patients with Rheumatoid Arthritis [THU0149] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- Weinblatt M, et al. Sustained Efficacy and Comparable Safety and Immunogenicity After Transition to SB5 (an Adalimumab Biosimilar) vs Continuation of the Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III study [FRI0161] – Friday, June 10, 2016, 11.50am BST, Poster Area
- Kay J, et al. Secondary Efficacy Results up to Week 24 from a Phase III Study Comparing SB5 (an Adalimumab Biosimilar) with Adalimumab Reference Product in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy [THU0138] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- Genovese MC, et al. Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 From a Phase III Study Comparing SB5 (an Adalimumab Biosimilar) With Adalimumab Reference Product in Patients With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy [THU0146] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- A Phase I Pharmacokinetic Study Comparing Pre-Filled Pen and Pre-Filled Syringe of SB5, an Adalimumab Biosimilar in Healthy Subjects [Abstract only]
BENEPALI is an etanercept biosimilar to the reference product Enbrel®7. BENEPALI is approved in Europe for the treatment of adults with moderate to severe RA, psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis. BENEPALI is currently available in five European countries, namely, the UK, Germany, Norway, Sweden and the Netherlands.
FLIXABI is an infliximab biosimilar to the reference product Remicade®8. FLIXABI is approved in Europe for the treatment of adults with RA, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis. FLIXABI can also be used in patients 6–17 years old with severe, active Crohn’s disease or severely active ulcerative colitis.
SB5 is an investigational treatment being developed as a biosimilar to the reference product Humira®.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies, and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.
Biogen Safe Harbor
This press release includes forward-looking statements, including statements about the potential benefits of our products and programs and expected timing of results from clinical trials. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "will," and other words and terms of similar meaning. You should not place undue reliance on these statements. Drug development and commercialization is a lengthy and complex process, which involves a high degree of risk. Factors that could cause actual results to differ materially from our current expectations include: the risk that unexpected concerns may arise from additional data or analysis, or regulatory authorities may require additional data or information or further studies, or may fail to approve, or refuse to approve, or may delay approval of our biosimilar drug candidates risks related to our dependence on third parties for the development and commercialization of biosimilars; risks of legal actions, regulatory scrutiny or other challenges to biosimilars; and the risks of other unexpected hurdles. For more detailed information on the risks and uncertainties associated with our drug development and commercialization activities, please review the Risk Factors section of our most recent annual or quarterly report filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations, and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
i Enbrel is a registered trademark of Wyeth LLC.
ii Emery P, et al. Long-term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison Between Continuing SB4 and Switching from Etanercept Reference Product to SB4. Poster presented at the European League Against Rheumatism (EULAR) Annual Congress, 9 June 2016, London UK. Samsung Bioepis data
iii Remicade is a registered trademark of Janssen Biotech, Inc.
iv Smolen JS, et al. Comparable Safety and Immunogenicity and Sustained Efficacy after Transition to SB2 (an Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study. Poster presented at the European League Against Rheumatism (EULAR) Annual Congress, 9 June 2016, London UK. Samsung Bioepis data.
v Humira is a registered trademark of Abbvie Biotechnology Ltd.
vi Weinblatt M, et al. Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) vs Continuation of the Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Study. Poster presented at the European League Against Rheumatism (EULAR) Annual Congress, 9 June 2016, London UK. Samsung Bioepis data
BIOGEN US MEDIA CONTACT:
Jason Glashow, +1 781-464-3260
BIOGEN EU MEDIA CONTACT:
Shannon Altimari, +41 41 392 1677
BIOGEN INVESTOR CONTACT:
Mike Hencke, +1 781-464-2442
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cushman & Wakefield To Acquire Its Irish Affiliate From Sherry FitzGerald Group16.7.2018 13:49 | Pressemelding
Global real estate services firm Cushman & Wakefield today announces it has entered into a definitive agreement to acquire the commercial property arm of Sherry FitzGerald Group in the Republic of Ireland. The deal is expected to complete in early September 2018. Cushman & Wakefield already has a 20% stake in the Irish commercial property business which operated as its exclusive affiliate in the Republic – rebranding two years ago as Cushman & Wakefield Ireland. The firm, which has more than 100 commercial property professionals and offices in Dublin, Limerick and Galway, will now be fully integrated into Cushman & Wakefield, one of the world’s largest real estate services firms with 48,000 employees in approximately 400 offices and 70 countries. Managing Director Aidan Gavin becomes Cushman & Wakefield’s Head of Ireland and will also sit on the firm’s UK & Ireland Executive Committee. Cushman & Wakefield will maintain its close affiliate relationship with the wider Sherry FitzGerald G
Fischer & Schickendantz and Solution Alliance SRL Adopt Andersen Brand in Uruguay16.7.2018 13:30 | Pressemelding
Fischer & Schickendantz, led by Juan Federico Fischer, and Solution Alliance SRL, led by Juan Ignacio Troccoli, have rebranded this week as Andersen Tax & Legal, a member firm of Andersen Global. The firm, based in Montevideo, entered a Collaboration Agreement with Andersen Global in September 2017, and is now a fully integrated member of the global verein. Juan Federico Fischer remarked, “Andersen is a symbol of quality and is recognized worldwide by both clients and professionals, and is ahead of the game in terms of creating a global firm with integrated tax and legal services. We are truly excited to officially be part of the team.” “Throughout their time with us as a collaborating firm and now a member firm, the team in Uruguay has demonstrated a deep commitment to providing seamless, best-in-class service. Additionally, Juan Federico is a member of Andersen Global’s Latin American regional board, and is the true embodiment of the values that our organization represents. I look fo
Norsk Titanium Produces Space Demonstration Hardware16.7.2018 11:00 | Pressemelding
Norsk Titanium (Norsk), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, has produced an Expansion Nozzle demonstrator in support of the European Space Agency’s Technology Research Programme (TRP). The TRP is an European Space Agency (ESA) technology development effort supporting all of ESA’s fields of activity across the entire spectrum of technical disciplines, providing the technological nucleus for most future developments. Norsk was awarded a TRP contract with the ESA in 2014 to explore the application of Norsk’s Rapid Plasma Deposition™ (RPD™) process to space applications. Through the TRP contract, Norsk has refined its material characterization and quality assurance processes, while providing ESA valuable insight into the application of additive processes to their unique needs. The culmination of this effort was the production of an Expansion Nozzle demonstrator. The Expansion Nozzle utilizes the latest RPD™ desi
CALVIN KLEIN Fragrances Announces Lupita Nyong'o and Saoirse Ronan as Faces of CALVIN KLEIN WOMEN16.7.2018 11:00 | Pressemelding
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE:PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE:COTY], today revealed the worldwide print advertising campaign for the new fragrance CALVIN KLEIN WOMEN , the first CALVIN KLEIN fragrance to be developed under the vision of Chief Creative Officer, Raf Simons. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005092/en/ CALVIN KLEIN WOMEN The campaign features Lupita Nyong'o and Saoirse Ronan. Award-winning actors and voices of their generation, both women are universally recognized for their unique talent, creativity, intelligence and strength of character. Directed by artist Anne Collier with creative direction from Lloyd & Co., the campaign champions iconic women and celebrates heroines of contemporary culture. Lupita and Saoirse are featured in the print campaign, in a pair of striking and direct portraits, positioned next to chosen figure
Bank of America Reports Second-Quarter 2018 Financial Results16.7.2018 10:45 | Pressemelding
Bank of America reported its second-quarter 2018 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005280/en/ Bank of America newsroom at https://newsroom.bankofamerica.com Bank of America Investor Relations website at http://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 8:30 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can also listen to a live audio webcast of the conference ca
Bank of Singapore is the First Singapore Private Bank to Receive Regulatory Approval to Open a Wealth Management Subsidiary in Luxembourg16.7.2018 09:36 | Pressemelding
Bank of Singapore today announced that it has been granted an investment company licence to operate a wealth management subsidiary in Luxembourg – a first for a Singapore private bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005252/en/ (Photo: BOSWM) Bank of Singapore, through this new subsidiary, BOS Wealth Management Europe Société Anonyme (S.A.), will be able to offer a comprehensive range of customised private banking solutions and investment advisory services to its ultra-high and high net worth clients in the European Economic Area (“EEA”) and the United Kingdom (“UK”). The EEA comprises the European Union (EU) countries and Iceland, Liechtenstein and Norway. Currently, Bank of Singapore serves its European clients from its Singapore headquarters and through its parent company OCBC Bank’s London office. There has been robust growth in assets under management from EEA clients as they hold Singapore in high